REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Announces Presentation at the 60th Annual ESPE Meeting

07 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

01 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

12 May 2022 15:05:01 By Nasdaq GlobeNewswire

Rezolute to Host Corporate Update Call on May 4, 2022

04 May 2022 15:01:00 By Nasdaq GlobeNewswire

Rezolute, Inc. Announces Closing of Registered Direct Offering

04 May 2022 08:33:12 By Nasdaq GlobeNewswire

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

01 May 2022 22:25:14 By Nasdaq GlobeNewswire

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

01 May 2022 13:00:00 By Nasdaq GlobeNewswire

RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022

26 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

Rezolute Joins the Rare Disease Company Coalition

29 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

23 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

22 Feb 2022 06:00:02 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress

09 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

12 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

13 Oct 2021 07:10:40 By Nasdaq GlobeNewswire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

12 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

22 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

15 Sep 2021 15:56:23 By Nasdaq GlobeNewswire

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

09 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

07 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

10 Aug 2021 06:00:01 By Nasdaq GlobeNewswire